News | January 07, 2024
Pharmaids Pharmaceuticals to acquire Adita Bio Sys in share swap
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
The acquisition of the shares of Adita result in growth opportunities in line with strategic objectives of the company
The company has received five final approvals
Vyleesi is the first and only as-needed treatment approved by the Food and Drug Administration (FDA) for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD)
Development services for gene and cell therapies is planned to begin first in 2025
Granules Pharmaceuticals gets 5 observations from USFDA on completion of GMP inspection
Laurus Synthesis receives Form 483 with 5 observations from USFDA
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
Dr. Reddy's Laboratories has been issued a Form 483 with three observations
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Prior to joining Alembic, he was working with Lupin Limited for more than 11 years
Subscribe To Our Newsletter & Stay Updated
